The Journey Of Nemonoxacin

Author:   Chi-Hsin Richard King
Publisher:   Chi-Hsin Richard King
ISBN:  

9781971588322


Pages:   196
Publication Date:   27 March 2026
Format:   Paperback
Availability:   Available To Order   Availability explained
We have confirmation that this item is in stock with the supplier. It will be ordered in for you and dispatched immediately.

Our Price $44.56 Quantity:  
Add to Cart

Share |

The Journey Of Nemonoxacin


Overview

The narrative chronicled in the book offers a comprehensive account of the journey of Nemonoxacin, tracing its evolution from its inception as a novel chemical entity to its successful commercial launch in various formulations. Nemonoxacin debuted in the pharmaceutical market as Taigexyn(R) Capsule, a 250 mg oral dosage form, approved in Taiwan in 2014 and subsequently in China in 2016. It further expanded its presence with the introduction of Taigexyn(R) Intravenous Injection, a 500 mg/250 mL preparation for parenteral administration, which gained approval in Taiwan (2020), China (2021), and Russia (2022). The international reach of Taigexyn(R) has been significantly enhanced through a strategic licensing agreement with R-Pharm, which opened doors to the markets in Russia, Turkey, and all the member countries of the Commonwealth of Independent States (CIS). Moreover, partnerships have secured exclusive distribution and sales rights for Nemonoxacin in key global markets. These include an agreement with Productos Científicos S.A. de C.V. for the Latin American region, with Luminarie for English-speaking countries such as Canada, New Zealand, and Australia, and with Y.S.P. Industries (M) Sdn. Bhd. for Malaysia and Singapore. Nemonoxacin's designation as a ""Qualified Infectious Disease Product (QIDP)"" and its receipt of ""Fast Track Status"" from the US FDA for the treatment of Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI) underscores its therapeutic potential and significance. These designations have paved the way for Phase III clinical development in the United States, focusing on these indications with the backing of substantial financial support from prominent pharmaceutical partners. This progression marks a pivotal phase in Nemonoxacin's journey towards addressing unmet medical needs and improving patient care on a global scale.

Full Product Details

Author:   Chi-Hsin Richard King
Publisher:   Chi-Hsin Richard King
Imprint:   Chi-Hsin Richard King
Dimensions:   Width: 15.20cm , Height: 1.10cm , Length: 22.90cm
Weight:   0.268kg
ISBN:  

9781971588322


ISBN 10:   1971588326
Pages:   196
Publication Date:   27 March 2026
Audience:   General/trade ,  General
Format:   Paperback
Publisher's Status:   Active
Availability:   Available To Order   Availability explained
We have confirmation that this item is in stock with the supplier. It will be ordered in for you and dispatched immediately.

Table of Contents

Reviews

Author Information

Tab Content 6

Author Website:  

Countries Available

All regions
Latest Reading Guide

MRGC26

 

Shopping Cart
Your cart is empty
Shopping cart
Mailing List